论文部分内容阅读
目的探讨顺铂(CDDP)在人体内诱导原发性肝癌(PHC)细胞凋亡(APO)的情况及其与多药耐药性(MDR)之间的关系。方法将30例PHC患者分成两组:CDDP治疗组16例,患者在术前行CDDP诱导治疗(30mg/d,静脉滴注,连续4d);对照组14例,术前未给予任何治疗药物。流式细胞仪(FCM)检测两组患者手术标本的APO和MDR表达情况,并作相关分析。结果CDDP组APO为(7·72±6·66)%较对照组明显增高(P<0·01),CDDP治疗组S期细胞比率(SP)及增殖指数(PI)分别为(3·01±2·98)%和(7·35±4·92)%,对照组为(8·30±5·49)%和(20·96±13·59)%,较对照组显著降低(P<0·01),两组MDR的表达无明显差异;CDDP组APO与MDR的表达呈负相关(r=-0·6,P<0·05)。结论CDDP在人体内能够诱导PHC细胞凋亡而起治疗作用;MDR的表达(P170)是CDDP诱导PHC凋亡的影响因素之一。PHC细胞的APO与MDR的表达存在负相关(P<0·05)。
Objective To investigate the role of cisplatin (CDDP) in inducing apoptosis of primary hepatocellular carcinoma (PHC) in human and its relationship with multidrug resistance (MDR). Methods Thirty patients with PHC were divided into two groups: 16 in the CDDP group, and 30 in the control group (CDDP induction, 30 mg / d, iv). In the control group, no treatment was given. Flow cytometry (FCM) was used to detect APO and MDR expression in surgical specimens from two groups of patients and to make correlation analysis. Results The APO of CDDP group was significantly higher than that of the control group (P <0.01). The percentage of cell cycle (SP) and proliferation index (PI) of the CDDP group were (3.01 ± 2.98% and 7.35 ± 4.92%, respectively, while those in the control group were (8 · 30 ± 5 · 49)% and (20 · 96 ± 13 · 59)%, respectively, which were significantly lower than those in the control group <0.01). There was no significant difference between the two groups in the expression of MDR. The expression of APO and MDR in CDDP group was negatively correlated (r = -0.6, P <0.05). Conclusions CDDP can induce apoptosis of PHC cells in human body and play a therapeutic role. The expression of MDR1 (P170) is one of the factors that affect the apoptosis of PHC induced by CDDP. There was a negative correlation between APO and MDR expression in PHC cells (P <0.05).